Cellectar Biosciences Inc (CLRB) concluded trading on Thursday at a closing price of $2.33, with 2.36 million shares of worth about $5.5 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -10.73% during that period and on June 27, 2024 the price saw a loss of about -19.38%. Currently the company’s common shares owned by public are about 35.85M shares, out of which, 34.69M shares are available for trading.
Stock saw a price change of -16.79% in past 5 days and over the past one month there was a price change of -21.28%. Year-to-date (YTD), CLRB shares are showing a performance of -15.88% which increased to 26.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.56 but also hit the highest price of $4.45 during that period. The average intraday trading volume for Cellectar Biosciences Inc shares is 674.14K. The stock is currently trading -23.03% below its 20-day simple moving average (SMA20), while that difference is down -25.20% for SMA50 and it goes to -23.32% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cellectar Biosciences Inc (NASDAQ: CLRB) currently have 35.85M outstanding shares and institutions hold larger chunk of about 25.47% of that.
The stock has a current market capitalization of $83.53M and its 3Y-monthly beta is at 1.00. It has posted earnings per share of -$3.08 in the same period. It has Quick Ratio of 2.54 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLRB, volatility over the week remained 9.35% while standing at 6.76% over the month.
Stock’s fiscal year EPS is expected to rise by 53.46% while it is estimated to increase by 61.14% in next year.
Coverage by ROTH Capital stated Cellectar Biosciences Inc (CLRB) stock as a Buy in their note to investors on January 21, 2020, suggesting a price target of $10 for the stock. On September 13, 2019, ROTH Capital Initiated their recommendations, while on December 21, 2016, Ladenburg Thalmann Initiated their ratings for the stock with a price target of $2.70.
